MedTrace Logo

Effect of Medicago Sativa on Oral Glucose Tolerance in Healthy Adults

NCT03714438 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-02-21

No results posted yet for this study

Summary

Previous preclinical investigations have found that Medicago sativa promotes the decrease of glucose concentrations. To evaluate the acute effect of Medicago sativa administration on glucose tolerance, insulin secretion, and insulin sensitivity in healthy individuals.

Conditions

  • Glucose Tolerance

Interventions

DRUG

Medicago Sativa

Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.

DIETARY_SUPPLEMENT

Placebo

Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Lizet Yadira Rosales-Rivera, PhD Science · Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-07
Primary Completion
2018-01-11
Completion
2018-01-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714438 on ClinicalTrials.gov